The Week in Review: IPO and M&A Pipeline

Beijing Pharma plans a large IPO in Hong Kong; Xiangxue Pharma and Guangdong By-Health Biotech (SHEZ: 300146) will IPO on the ChiNext exchange; Sihuan Pharma will pay $371 million to acquire rival Dupromise Holdings; after one year. Novartis has not closed its $125 million acquisition of Zhejiang Tianyuan Bio; Jiangsu Wuzhong Industrial was awarded a $1.8 million subsidy to develop a cancer drug; ShangPharma Corporation reported solid, but unexciting Q3 revenues; and Aoxing was given a manufacturing license for its narcotic API joint venture. More details…. Stock Symbols: (SHEZ: 300147) (HKEX: 0460) (NYSE: NVS) (SHA: 600200) (NYSE: SHP) Pharma (AMEX: AXN)